1 hour ago
2
By Michael Erman
Feb 5 (Reuters) - Bristol Myers Squibb connected Thursday forecast 2026 results supra Wall Street estimates, saying that terms cuts to its humor thinner Eliquis volition assistance thrust up revenue, sending shares of the drugmaker up 4% successful premarket trading.
The institution projected full 2026 gross successful a scope of $46.0 cardinal to $47.5 billion, up of the $44.2 cardinal analysts person forecast, according to LSEG data, with the institution expecting Eliquis gross to emergence 10% to 15% this year.
Analysts had been expecting income of the humor thinner, which brought successful $14.4 cardinal successful 2025, to autumn importantly this twelvemonth owed to the little terms and due to the fact that the cause is 1 of the archetypal 10 medicines taxable to Medicare terms negotiations nether the Inflation Reduction Act.
But the institution said the lower terms for Eliquis volition assistance it debar penalties imposed by the U.S. government's Medicare wellness security program.
"The broader pricing dynamics starting this twelvemonth for Eliquis truly was the impetus to reevaluate our pricing strategy," Chief Commercialization Officer Adam Lenkowsky said successful an interview.
"Eliquis volition beryllium an important operator of maturation successful 2026."
Bristol Myers sells Eliquis with spouse Pfizer Inc. The 2 companies announced plans in June to commencement selling Eliquis straight to cash-paying U.S. patients astatine a discount of much than 40% and followed that up with a January 1 terms chopped to commercialized patients.
Bristol Myers said it expects an adjusted nett betwixt $6.05 and $6.35 per stock for 2026, besides supra the statement expert estimation of $6.02.
Q4 EARNINGS BEAT ESTIMATES ON OPDIVO SALES
The drugmaker besides reported fourth-quarter results that bushed Wall Street estimates connected the beardown show of crab immunotherapy Opdivo.
The U.S. drugmaker posted an adjusted nett of $1.26 per share, up of an mean expert estimation of $1.12. Quarterly revenues roseate 1% to $12.5 billion, topping a statement forecast of $12.28 billion.
Opdivo income accrued 9% to $2.69 cardinal - up of forecasts of $2.34 cardinal - and the caller subcutaneously administered mentation of the cause added different $133 million.
Lenkowsky said Opdivo’s spot successful the 4th came from request from caller indications for the cancer drug, arsenic good arsenic beardown marketplace stock successful first-line lung crab treatment.
Also successful the interview, Chief Financial Officer David Elkins said the company's cost-cutting programme has already delivered $1 cardinal retired of a planned $2 cardinal successful full savings. The institution said it chopped its spending connected probe and improvement for caller drugs by 18% successful 2025 compared with the erstwhile year.
(Reporting by Michael Erman, further reporting by Christy Santhosh successful Bengaluru; Editing by Tom Hogue)
English (CA) · 
English (US) · 
Spanish (MX) ·